Clovis Oncology Inc.

(CLVS) Trade

By |

Profile

Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm target its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.

Contact Information

Website: www.clovisoncology.com
Email: bburkart@clovisoncology.com
Main Phone: +1 303 625-5000
Address: 5500 Flatiron Parkway
Address 2: Suite 100
State: CO
City / Town: Boulder
Country: USA
Postal Code: 80301

Issuer Information

Exchange: NGS
CEO: Patrick J. Mahaffy
Employees: 468
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More

Profile

Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm target its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.

Contact Information

Website: www.clovisoncology.com
Email: bburkart@clovisoncology.com
Main Phone: +1 303 625-5000
Address: 5500 Flatiron Parkway
Address 2: Suite 100
State: CO
City / Town: Boulder
Country: USA
Postal Code: 80301

Issuer Information

Exchange: NGS
CEO: Patrick J. Mahaffy
Employees: 468
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More
$ 3.22 $ 0.01 (0.31%)
Last Price 3.22 Change $ 0.01 Change % 0.31 Tick N/A
Bid 3.21 Bid Size 2,400.00 Ask 3.22 Ask Size 600.00
Open 3.23 High 3.32 Low 3.19 Prev Close 3.21
Last Trade Volume 1 mi 52 Wk Hi 32.05 52 Wk Low 3.01
Market Cap 175.7 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 54,656,539.00 EPS (TTM) -7.50 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 15 61
Number of Buys 7 24
Number of Sells 8 37
Net Activity -27459 -429324
Last 10 Buys Shares
Edward J. McKinley 1,000
Edward J. McKinley 1,000
Edward J. McKinley 1,000
Edward J. McKinley 1,000
Erle T. Mast 1,000
Thorlef Spickschen 1,000
Gillian C. Ivers-Read 1,000
Edward J. McKinley 1,000
Paul H. Klingenstein 1,000
James C. Blair 1,000
Last 10 Sell Shares
Thorlef Spickschen 1,000
Thorlef Spickschen 1,000
Thorlef Spickschen 1,000
Gillian C. Ivers-Read 1,000
Gillian C. Ivers-Read 1,000
Thorlef Spickschen 1,000
Gillian C. Ivers-Read 1,000
Thorlef Spickschen 1,000
Gillian C. Ivers-Read 1,000
Gillian C. Ivers-Read 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 97 97 97 97
Low Target Price Estimate 72 72 72 72
Mean Target Price Estimate 84.14 84.14 84.14 84.14
Standard Deviation 9.08 9.08 9.08 9.08
Date of Most Recent Estimate 06/05/18 05/09/18 05/09/18 06/05/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 6 7 7 8
Moderate Buy 1 1 2 2
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.56 1.5 1.5 1.46